Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

BACKGROUND: EML4-ALK is a distinct molecular entity that is highly sensitive to ALK tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors (ICIs) have not proved efficacy in ALK-positive non-small cell lung cancer so far. In this study, we performed a mouse clinical trial using EML4-ALK tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyo, Kyoung-Ho, Lim, Sun Min, Park, Chae-Won, Jo, Ha-Ni, Kim, Jae Hwan, Yun, Mi-Ran, Kim, Dohee, Xin, Chun-Feng, Lee, Wongeun, Gheorghiu, Bianca, Hong, Min Hee, Kim, Hye Ryun, Shim, Hyo Sup, Jang, Mi, Lee, Sung Sook, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394300/
https://www.ncbi.nlm.nih.gov/pubmed/32727812
http://dx.doi.org/10.1136/jitc-2020-000970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394300/
https://www.ncbi.nlm.nih.gov/pubmed/32727812
http://dx.doi.org/10.1136/jitc-2020-000970

Ejemplares similares